Pharmacodynamic studies clarified that AJH may directly down-regulate the expression of Smad3 and TGF-β1, or inhibit the TGF-β1/Smad3 signaling pathway by increasing the expression of DCN to achieve airway remodeling intervention in COPD rats [31,32]. This evidence concerns the gene SMAD3 and chronic obstructive pulmonary disease.